North American Brachytherapy Market Size to Reach $1.67 Billion by 2035

North American brachytherapy market size reached $0.82 billion in 2025 and is projected to expand to $1.67 billion by 2035, growing at a CAGR of 7.4% during the forecast period (2026–2035). Market growth is supported by increasing cancer prevalence, rising adoption of targeted radiotherapy, and continued investment in oncology infrastructure.

KEY MARKET DRIVERS

• Rising incidence of prostate and breast cancer across aging populations
• Increased hospital investments in radiation oncology departments
• Growing preference for localized radiation therapies over systemic treatments
• Expansion of reimbursement coverage for minimally invasive cancer procedures
• Advancements in imaging and treatment planning technologies

Browse the full report description of “North America Brachytherapy Market Size, Share & Trends Analysis Report by Indication (Breast Cancer, Gynecological Cancer, Prostate Cancer, Skin Cancer, Brain Cancer, and Others), and by Type (Low-Dose Rate (LDR) Brachytherapy and High-Dose Rate (HDR) Brachytherapy), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/north-american-brachytherapy-market

REGIONAL ANALYSIS

North America represents a well-established and expanding market for brachytherapy, supported by structured healthcare systems, high healthcare expenditure, and strong regulatory oversight. The United States accounts for the majority of regional demand due to the high prevalence of cancer and the widespread availability of specialized cancer treatment centers. According to data from the American Cancer Society, more than 2 million new cancer cases are diagnosed annually, sustaining consistent procedural volumes for radiation-based therapies. Federal reimbursement programs, including Medicare and Medicaid, continue to support access to radiotherapy services, while private insurers increasingly cover brachytherapy for prostate, breast, and gynecological cancers. In Canada, public healthcare funding and provincial cancer agencies facilitate standardized access to radiation oncology services, contributing to steady market participation across academic and community hospitals.

COMPETITIVE LANDSCAPE

Key companies operating in the North American brachytherapy market include Elekta, Varian Medical Systems, Eckert & Ziegler, Theragenics, IsoAid, iCAD, BEV Radiology, and CIVCO Medical Solutions.

These companies operate across equipment manufacturing, radioactive source supply, treatment planning software, and clinical workflow solutions. Market participation is governed by strict regulatory standards set by the U.S. Food and Drug Administration and national radiation safety authorities, which influence procurement cycles and technology adoption rates across healthcare institutions.

RECENT MARKET DEVELOPMENTS

• In October 2024, a cancer patient in Canada received treatment with actinium-225 DOTATATE, a rare radioisotope, under a clinical trial for neuroendocrine tumours (NETs). This theranostic approach integrates diagnostic imaging with targeted radiation to identify and destroy tumour cells. The multi-center trial across three Canadian hospitals is assessing the therapy’s safety and effectiveness compared with standard treatments for patients with advanced disease.
• In March 2025, Elekta AB announced an upgraded Flexitron HDR brachytherapy platform with enhanced user interface and real-time planning capabilities. The development supports streamlined clinical workflows and more precise treatment planning in oncology facilities.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Indication
  • By Type 
• Regions Covered-
  • North America
• Competitive Landscape - Becton, Dickinson and Company (BD), Elekta AB, Eckert & Ziegler BEBIG, Theragenics Corp., Varian Medical Systems, Inc., among others.

 Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

North American Brachytherapy Market Report Segment

By Indication

• Breast Cancer
• Gynecological Cancer
• Prostate Cancer
• Skin Cancer
• Brain Cancer
• Others

By Type 

• Low-Dose Rate (LDR) Brachytherapy
• High-Dose Rate (HDR) Brachytherapy
• Others

North American Brachytherapy Market Report Segment by Region

• United States
• Canada

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-brachytherapy-market